Pa. Federal Judge Dismisses Jardiance Injury Case, Allows Plaintiff to Amend

PITTSBURGH — A Pennsylvania federal judge has dismissed without prejudice a complaint alleging the makers of Jardiance negligently designed the type 2 diabetes drug and failed to adequately warn of the risk of ketoacidosis, ruling that the pleadings were not specific enough.

In a May 31 order, Chief Judge Joy Flowers Conti of the U.S. District Court for the Western District of Pennsylvania gave the plaintiff one more chance to replead his claims of negligence, fraudulent misrepresentation, negligent misrepresentation, negligent design, fraudulent concealment, and fraud.

William Bell began taking Jardiance (empagliflozin) on June 2015, to treat his type 2 diabetes. …